A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(12 sites)

United States

Yale Cancer Center-Yale University, New Haven, Connecticut

START Midwest, Grand Rapids, Michigan

Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

MD Anderson Cancer Center, Houston, Texas

NEXT Oncology, San Antonio, Texas

NEXT Oncology, Fairfax, Virginia

France

Centre Leon Berard, Lyon

Institut de Cancerologie de l'Ouest (ICO)- CRLCC Rene Gauducheau, Saint-Herblain

Gustave Roussy Cancer Campus Grand Paris- (Institut de Cancerologie Gustave-Roussy), Villejuif

Spain

Hospital Universitari Vall d'Hebron, Barcelona

NEXT Quiron-Barcelona, Barcelona

START Madrid CIOCC Hospital Universitario HM Sanchinarro, Madrid